Predicting Drug‐Resistant Mutations of HIV Protease

This publication has 16 references indexed in Scilit:

• Catalysis and Linear Free Energy Relationships in Aspartic Proteases
  Biochemistry, 2006
• Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA, and PDLD/S-LRA calculations of ligands binding to an HIV protease
  Proteins-Structure Function and Bioinformatics, 2000
• Counteracting HIV-1 Protease Drug Resistance: Structural Analysis of Mutant Proteases Complexed with XV638 and SD146, Cyclic Urea Amides with Broad Specificities
  Biochemistry, 1998
• Cyclic HIV-1 Protease Inhibitors Derived from Mannitol: Synthesis, Inhibitory Potencies, and Computational Predictions of Binding Affinities
  Journal of Medicinal Chemistry, 1997
• Molecular Basis of HIV-1 Protease Drug Resistance: Structural Analysis of Mutant Proteases Complexed with Cyclic Urea Inhibitors
  Biochemistry, 1997
• Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2‘ Structure−Activity Relationship, and Molecular Recognition of Cyclic Ureas
  Journal of Medicinal Chemistry, 1996
• Kinetic Characterization and Cross-Resistance Patterns Of HIV-1 Protease Mutants Selected under Drug Pressure
  Biochemistry, 1995
• Multiple Mutations in the Human Immunodeficiency Virus Protease Gene Are Responsible for Decreased Susceptibility to Protease Inhibitors
  Antiviral Chemistry and Chemotherapy, 1995
• DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein
  Antimicrobial Agents and Chemotherapy, 1994
• Active human immunodeficiency virus protease is required for viral infectivity.
  Proceedings of the National Academy of Sciences, 1988